Showing results (61-70 of 141) with videos related to

Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndromeRazelle Kurzrock, Hagop M Kantarjian, Michelle A Blascovich, et al.
Cancer Investigation|February 25, 2009
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agentsJeanny B Aragon-Ching, Yang-Min Ning, Clara C Chen, et al.
BJU International|January 22, 2009
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancerJeanny B Aragon-Ching, Lokesh Jain, James L Gulley, et al.
The Journal of Urology|April 20, 2010
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancerWilliam D Figg, Sukyung Woo, Wenhui Zhu, et al.
Plos One|January 6, 2011
A phase II trial of sorafenib in metastatic melanoma with tissue correlatesPatrick A Ott, Anne Hamilton, Christina Min, et al.
Clinical Lung Cancer|October 31, 2013
A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortiumScott A Laurie, Glenwood D Goss, Frances A Shepherd, et al.
Nature Communications|September 11, 2021
Functional basis of electron transport within photosynthetic complex IKatherine H Richardson, John J Wright, Mantas Šimėnas, et al.
BJU International|April 18, 2007
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancerWilliam D Figg, Haiqing Li, Tristan Sissung, et al.
Investigational New Drugs|September 15, 2010
An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinomaGeorge P Kim, Michelle R Mahoney, Daniel Szydlo, et al.
The Lancet. Oncology|February 14, 2012
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialRavi A Madan, Mahsa Mohebtash, Philip M Arlen, et al.
Pageof 15